Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fetal gestational age 23 0/7 to 31 6/7 weeks~* Treated with expectant management~* Meets modified ACOG criteria for severe preeclampsia~* Willing and able to provide written, informed consent~Exclusion Criteria:~* Decision to deliver within 24 hours has been made~* Weight \> 150 kg~* Eclampsia~* Significant antecedent obstetrical problems~* Clinically significant fetal anomaly or chromosomal abnormalities~* Chronic renal disease~* Active hepatic disease, antiphospholipid antibody syndrome, or lupus~* Unstable medical or psychiatric disorder~* Need for use of digitalis like products~* History of anaphylactic allergic reactions~* Prior use of antibodies/fab fragments from sheep~* Serum creatinine ≥ 2.0 mg/dL~* Platelet count \< 50,000~* Pulmonary edema~* Estimated fetal weight \< 5th percentile

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMAG-423 (digoxin immune fab) (Type: ACTIVE_COMPARATOR): AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline, 30 minute IV infusion, every 6 hours x 4 days

Based on this trial design, predict the completion outcome and termination type (if applicable).